This Article Full Text Full Text (PDF) All Versions of this Article: 28/4/387    most recent Final Manuscript Author Manuscript Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schumacher, M. Articles by Baulieu, E.-E. Search for Related Content PubMed PubMed Citation Articles by Schumacher, M. Articles by Baulieu, E.-E.

Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System

Unité Mixte de Recherche 788, Institut National de la Santé et de la Recherche Médicale, and University Paris-Sud 11, 94276 Kremlin-Bicêtre, France

Correspondence: Address all correspondence and requests for reprints to: Dr. Michael Schumacher, INSERM UMR 788, 80, rue du Général Leclerc, 94276 Kremlin-Bicêtre, France. E-mail: Michael.Schumacher{at}kb.inserm.fr

The utility and safety of postmenopausal hormone replacement therapy has recently been put into question by large clinical trials. Their outcome has been extensively commented upon, but discussions have mainly been limited to the effects of estrogens. In fact, progestagens are generally only considered with respect to their usefulness in preventing estrogen stimulation of uterine hyperplasia and malignancy. In addition, various risks have been attributed to progestagens and their omission from hormone replacement therapy has been considered, but this may underestimate their potential benefits and therapeutic promises. A major reason for the controversial reputation of progestagens is that they are generally considered as a single class. Moreover, the term progesterone is often used as a generic one for the different types of both natural and synthetic progestagens. This is not appropriate because natural progesterone has properties very distinct from the synthetic progestins. Within the nervous system, the neuroprotective and promyelinating effects of progesterone are promising, not only for preventing but also for reversing age-dependent changes and dysfunctions. There is indeed strong evidence that the aging nervous system remains at least to some extent sensitive to these beneficial effects of progesterone. The actions of progesterone in peripheral target tissues including breast, blood vessels, and bones are less well understood, but there is evidence for the beneficial effects of progesterone. The variety of signaling mechanisms of progesterone offers exciting possibilities for the development of more selective, efficient, and safe progestagens. The recognition that progesterone is synthesized by neurons and glial cells requires a reevaluation of hormonal aging.

This article has been cited by other articles:

				P. Luciani, C. Deledda, F. Rosati, S. Benvenuti, I. Cellai, F. Dichiara, M. Morello, G. B. Vannelli, G. Danza, M. Serio, et al. Seladin-1 Is a Fundamental Mediator of the Neuroprotective Effects of Estrogen in Human Neuroblast Long-Term Cell Cultures Endocrinology, September 1, 2008; 149(9): 4256 - 4266. [Abstract] [Full Text] [PDF]

				B. Liu and L. A. Arbogast Phosphorylation State of Tyrosine Hydroxylase in the Stalk-Median Eminence Is Decreased by Progesterone in Cycling Female Rats Endocrinology, April 1, 2008; 149(4): 1462 - 1469. [Abstract] [Full Text] [PDF]